Drug Profile

Induced pluripotent stem cell therapeutic - Myogenica

Alternative Names: CD54+ allogeneic muscle progenitor cell; MyoPAXon

Latest Information Update: 03 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Myogenica
Class Induced pluripotent stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Duchenne muscular dystrophy

Most Recent Events

20 Mar 2025 Phase-I clinical trials in Duchenne muscular dystrophy in USA (IM) (NCT06692426)
18 Nov 2024 Myogenica plans a phase I trial for Duchenne muscular dystrophy in December 2024 (IM) (NCT06692426)
17 Jul 2024 Preclinical trials in Duchenne muscular dystrophy in USA (Parenteral), prior to July 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com